Carlos Fernández de Larrea

Statistics

Publications

Citations

5.4K

H-Index

Active since

1985

Affiliations

Consorci Institut D'Investigacions Biomediques August Pi I Sunyer(Current)

Universitat de Barcelona

Hospital Clínic de Barcelona

Centro de Investigación Biomédica en Red de Cáncer

Centro de Investigación del Cáncer

Carlos Fernández de Larrea is an author at Consorci Institut D'Investigacions Biomediques August Pi I Sunyer specializing in medicine, multiple myeloma, and hematology.

ORCID

Publications per year

1985–2025

Publications

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

Jesús F. San Miguel, Binod Dhakal, Kwee Yong et al. · New England Journal of Medicine · 2023 · 733 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Constantine S. Tam, Stephen Opat, Shirley D’Sa et al. · Blood · 2020 · 448 citations · Full text

Medicine, Hematology, Pharmacology +4

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

Eric L. Smith, Kim Harrington, Reed Masakayan et al. · Science Translational Medicine · 2019 · 385 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

María‐Victoria Mateos, Shaji Kumar, Meletios Α. Dimopoulos et al. · Blood Cancer Journal · 2020 · 275 citations · Full text

Medicine, Hematology, Oncology +12

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

Meletios Α. Dimopoulos, Judith Trotman, Alessandra Tedeschi et al. · The Lancet Oncology · 2016 · 236 citations

Life Sciences, Immunology, Pharmacotherapy +12

1–5 of 85